Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RE40CA
- Development stage
- Preclinical
- Lead developer
- University of Kansas Medical Center
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
RE40CA is a standardized rosemary extract containing 40% carnosic acid, a naturally occurring bioactive diterpene. It is being investigated as a cancer chemopreventive agent, particularly for the prevention of invasive breast cancer (by preventing the progression of ductal carcinoma in situ to invasive ductal carcinoma) and prostate cancer. RE40CA acts by disrupting the interaction between β-catenin and B-cell lymphoma 9 (BCL9), thereby inhibiting the oncogenic Wnt/β-catenin signaling pathway. The development of RE40CA has been supported by the National Cancer Institute's (NCI) PREVENT Cancer Preclinical Drug Development Program.
- Other names
- rosemary extract standardized to 40% carnosic acidrosemary extract standardized to >40% carnosic acidstandardized rosemary extract
02
Targets
CTNNB1 (Beta-catenin)BCL9 (B-cell lymphoma 9 protein)
Beyond the preview
Go deeper on RE40CA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RE40CA.